CClinicalTrials.gg
CompletedNCT07475832Updated Mar 17, 2026

Comparison of Two Biometers in Dense Cataracts

An observational study in Cataract, sponsored by Berkeley Eye Center. Completed at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Berkeley Eye Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
61
Ages
45 Years and older
Sex
All
01

Study summary

This single-center, ambispective, observational study evaluates axial length acquisition in eyes with dense cataracts using the ARGOS swept-source optical coherence tomography biometer compared with the IOLMaster 700. Eligible subjects are pseudophakic adults who previously underwent complex cataract surgery because of poor visualization or poor red reflex from dense lens opacity and who had pre-operative biometry performed with both devices, with or without manual immersion A-scan ultrasonography. Enrolled subjects return for postoperative repeat biometry to confirm pre-operative measurements and to assess whether availability of an ARGOS axial length measurement may reduce the need for manual ultrasound A-scans in similar dense cataract cases. The planned sample size justification estimated that 61 patients were needed for statistical power, while 68 were originally targeted to allow for attrition in the prospective portion.

Read the detailed description

Cataract surgery is the most commonly performed surgical procedure in the United States. Accurate axial length measurement is critical for intraocular lens power selection, but optical biometry can be challenging in eyes with dense cataracts because of poor media penetration and limited signal acquisition. When optical axial length measurement cannot be obtained, manual immersion A-scan ultrasonography is often required, which adds workflow complexity, technician time, and patient time.

This study was designed to evaluate the performance of the ARGOS swept-source optical coherence tomography biometer in eyes with dense cataracts and to compare its axial length acquisition capability with that of the IOLMaster 700. The study also evaluates whether use of ARGOS, including enhanced retina visualization mode when needed, may reduce reliance on manual ultrasound biometry in this setting.

This is a single-center, ambispective, non-interventional observational study. The retrospective component involves review of prior cataract surgery cases in which pre-operative biometry had been performed with both the ARGOS and the IOLMaster 700 in eyes with dense cataracts associated with poor visualization or poor red reflex. The prospective component consists of a postoperative study visit in enrolled subjects for repeat biometry, allowing comparison of postoperative measurements with historical pre-operative values and assessment of whether successful ARGOS measurement could have reduced the need for confirmatory ultrasound testing.

The overall purpose of the study is to better characterize the utility of ARGOS biometry in dense cataracts and to assess its potential clinical value in reducing the need for manual A-scan ultrasonography in routine practice.

02

Conditions studied

  • Cataract

Browse trials for

03

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pseudophakic adults who previously underwent complex cataract surgery for poor red reflex or poor visualization due to dense cataract and had pre-operative biometry with both the ARGOS and IOLMaster 700.

Inclusion criteria

  • Adults aged 45 years and older
  • Previously underwent complex cataract removal by phacoemulsification with a clear corneal incision in one or both eyes more than 1 month before enrollment
  • Complex cataract removal was performed for poor red reflex or poor visualization due to lens density or opacification
  • Pre-operative dense cataract in the study eye, defined as greater than or equal to 3+ posterior subcapsular cataract, 3+ nuclear sclerotic cataract, 3+ cortical cataract, or any combination of these
  • Pre-operative biometry performed with both the ARGOS and IOLMaster 700
  • Other than cataract, clear intraocular media, with no corneal opacity or vitreous hemorrhage

Exclusion criteria

Exclusion Criteria:

  • Pre-operative mature or white cataract in the study eye
  • Any corneal abnormality, other than regular corneal astigmatism, that in the opinion of the investigator would confound study outcomes
  • History of or current retinal condition, or predisposition to retinal conditions, other than posterior vitreous detachment, that in the opinion of the investigator would confound study results
  • Amblyopia or strabismus in either eye
  • Nystagmus or other condition that would hamper axial length capture because of poor fixation
  • History of or current anterior or posterior segment inflammation of any etiology
  • Any form of ocular neovascularization
  • Diagnosed degenerative eye disorders
  • Acute or chronic disease or illness that, in the opinion of the investigator, would confound study results, including immunocompromised state, connective tissue disease, or clinically significant atopic disease
04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
61 participants (actual)
Patient registry
No

Groups and cohorts

  • Eligible pseudophakic subjects with prior dense cataracts

    Pseudophakic adult subjects who previously underwent complex cataract surgery because of poor visualization or poor red reflex from dense cataract and who had pre-operative biometry performed with the ARGOS and IOLMaster 700, with or without manual immersion A-scan ultrasonography. Enrolled subjects undergo postoperative repeat biometry for comparison with pre-operative measurements.

    Diagnostic Test: ARGOS biometer · Diagnostic Test: IOLMaster 700

Interventions

  • Diagnostic testARGOS biometer

    Swept-source optical coherence tomography biometer used for axial length measurement pre-operatively and at the postoperative study visit. Enhanced retina visualization mode may be used when needed.

  • Diagnostic testIOLMaster 700

    Swept-source optical coherence tomography biometer used for axial length measurement pre-operatively and at the postoperative study visit for comparison with ARGOS measurements.

05

What researchers measure

Primary outcomes

  1. Percentage of eyes with successful axial length acquisition

    Percentage of eyes in which axial length measurements were successfully acquired using the ARGOS biometer compared with the IOLMaster 700 in eyes with dense cataracts.

    Time frame: Pre-operative assessment and postoperative confirmation visit, up to 24 months after cataract surgery.

Secondary outcomes

  1. Percentage of eyes requiring ultrasound A-scan

    Percentage of eyes that required manual ultrasound A-scan because axial length measurement could not be obtained by optical biometry.

    Time frame: Pre-operative review and postoperative confirmation visit, up to 24 months after cataract surgery.

  2. Percentage of eyes requiring enhanced retina visualization mode

    Percentage of eyes in which enhanced retina visualization (ERV) mode was required to obtain axial length measurement.

    Time frame: Pre-operative review and postoperative confirmation visit, up to 24 months after cataract surgery.

  3. Difference between postoperative and pre-operative axial length measurements

    Difference between postoperative axial length measurements and pre-operative axial length measurements for ARGOS and IOLMaster 700.

    Time frame: Up to 24 months postoperatively.

06

Study locations

1 site
  • Berkeley Eye Center - Sugar Land
    Sugar Land, Texas 77478, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07475832
Lead sponsor
Berkeley Eye Center
Collaborators
Alcon Research
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Oct 11, 2023
Primary completion
Oct 15, 2025
Completion
Oct 15, 2025
Last update
Mar 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion